1
00:00:00,000 --> 00:00:03,500
Semaglutide research includes outcomes beyond body weight.

2
00:00:03,500 --> 00:00:09,750
The SELECT trial examined major cardiovascular events in a carefully defined group of adults.

3
00:00:09,750 --> 00:00:15,208
Participants had established cardiovascular disease and overweight or obesity, but no diabetes.

4
00:00:15,208 --> 00:00:19,875
Researchers randomly assigned semaglutide or placebo alongside standard medical care.

5
00:00:19,875 --> 00:00:26,542
The semaglutide group had fewer events in the combined outcome of cardiovascular death, nonfatal heart

6
00:00:26,542 --> 00:00:30,042
attack, or nonfatal stroke during follow-up.

7
00:00:30,042 --> 00:00:34,292
This is evidence about clinical events in that population.

8
00:00:34,292 --> 00:00:40,167
It does not establish the same benefit for every person, formulation, or indication.

9
00:00:40,167 --> 00:00:43,667
Adverse effects remain part of the assessment.